An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)

CompletedOBSERVATIONAL

Enrollment

2,437

Participants

Timeline

Start Date

July 14, 2022

Primary Completion Date

October 5, 2022

Study Completion Date

October 5, 2022

Conditions

Treatment of Venous Thromboembolism in Cancer PatientsVenous ThromboembolismCancer

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data

DRUG

Apixaban

Retrospective cohort analysis using United States Optum De-Identified Electronic Health Records data

Trial Locations (1)

Bayer, Wuppertal